16 reports

In refractory patients consider adding TZD or SGLT##I: Basal insulin + Mealtime insulin or GLP-## RA TZD SU or or SGLT##I Insulin or or DPP-##I Insulin GLP-## RA + or or TZD Insulin Metformin + Insulin (basal) + or DPP-##I or SGLT##I o

  • Type 2 Diabetes
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.

Direct Activation of the Angiotensin II Type-## Receptors Enhances Muscle Microvascular Perfusion, Oxygenation and Insulin Delivery in Male Rats".

  • Therapy
  • Type 2 Diabetes
  • Australia
  • World
  • Product Initiative

Direct Activation of the Angiotensin II Type-## Receptors Enhances Muscle Microvascular Perfusion, Oxygenation and Insulin Delivery in Male Rats".

  • Pharmaceutical
  • Therapy
  • Type 2 Diabetes
  • World
  • Product Initiative

Direct Activation of the Angiotensin II Type-## Receptors Enhances Muscle Micro vascular Perfusion, Oxygenation and Insulin Delivery in Male Rats".

  • Type 2 Diabetes
  • United States
  • Company
  • Product Initiative
  • ProMetic Life Sciences Inc.

A heavy tax on insulin delivery devices such as syringes also hinders effective disease management despite insulin availability.

  • Type 2 Diabetes
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Endocrine Disease
  • Type 2 Diabetes
  • World
  • Product Initiative
  • Novartis AG
  • Clinical Trial profile. 133 Trial Title
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

Diabetic Nephropathy Global Clinical Trials Review, H2, 2017 Summary GlobalData’s clinical trial report, “Diabetic Nephropathy Global Clinical Trials Review, H2, 2017" provides an overview of Diabetic Nephropathy clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic...

  • Clinical Trial
  • Endocrine Disease
  • Therapy
  • Type 2 Diabetes
  • World
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Clinical Trial
  • Endocrine Disease
  • Pharmaceutical
  • Type 2 Diabetes
  • World

NEVAN ELAM, SAID, " AB ## HAS THE POTENTIAL TO BE A CLEARLY DIFFERENTIATED PRODUCT THAT REPRESENTS A SIGNIFICANT ADVANCE IN BASAL INSULIN DELIVERY.

  • Pharmaceutical
  • Type 2 Diabetes
  • United States
  • Company
  • AntriaBio, Inc.
  • RECOMBINANT PEPTIDES TO AGONIZE INSULIN RECEPTOR FOR TYPE 1 AND TYPE 2 DIABETES - DRUG PROFILE
  • RECOMBINANT PEPTIDE TO AGONIZE INSULIN RECEPTOR FOR DIABETES - DRUG PROFILE

AEROGEN HAS GRANTED DANCE AN EXCLUSIVE WORLDWIDE LICENSE TO THEIR AEROSOL TECHNOLOGY FOR INSULIN DELIVERY.

  • Biopharmaceutical
  • Pathology
  • Type 2 Diabetes
  • United States
  • Company

NEVAN ELAM, SAID, " AB ## HAS THE POTENTIAL TO BE A CLEARLY DIFFERENTIATED PRODUCT THAT REPRESENTS A SIGNIFICANT ADVANCE IN BASAL INSULIN DELIVERY.

  • Pharmaceutical
  • Type 2 Diabetes
  • United States
  • Company
  • AntriaBio, Inc.

Direct Activation of the Angiotensin II Type-## Receptors Enhances Muscle Microvascular Perfusion, Oxygenation and Insulin Delivery in Male Rats".

  • Diabetes
  • Type 2 Diabetes
  • United States
  • Company
  • Product Initiative

Direct Activation of the Angiotensin II Type-## Receptors Enhances Muscle Microvascular Perfusion, Oxygenation and Insulin Delivery in Male Rats".

  • Diabetes
  • Type 2 Diabetes
  • United States
  • Company
  • Product Initiative

Direct Activation of the Angiotensin II Type-## Receptors Enhances Muscle Microvascular Perfusion, Oxygenation and Insulin Delivery in Male Rats".

  • Pharmaceutical
  • Therapy
  • Type 2 Diabetes
  • United States
  • Product Initiative

FDA Phase IIa safety study for ORMD-##, an oral insulin capsule based on the Company' s platform Protein Oral Delivery (POD) technology.

  • Pharmaceutical
  • Type 2 Diabetes
  • United States
  • Company
  • Product Initiative

FDA Phase IIa safety study for ORMD-##, an oral insulin capsule based on the Company' s platform Protein Oral Delivery (POD™) technology.

  • Pharmaceutical
  • Type 2 Diabetes
  • United States
  • Company
  • Product Initiative